Alpha Cognition Enrolls First Patient in BEACON Study Evaluating Alzheimer’s Drug ZUNVEYL
Alpha Cognition Inc. announced that the first patient has been enrolled in its BEACON Phase 4 real-world effectiveness study evaluating the impact of its Alzheimer’s treatment ZUNVEYL® in long-term care settings. The study will enroll about 200 patients across multiple clinical sites to assess cognition, neuropsychiatric symptoms, safety, and tolerability, with topline results expected in late 2026. 
Alpha Cognition Enrolls First Patient in BEACON Study Evaluating Alzheimer’s Drug ZUNVEYL